1232:
1218:
281:(JX-594) was developed using the SOLVE (Selective Oncolytic Vaccinia Engineering) platform. This platform may be used to optimize virus targeting to specific cancer types, to select transgenes to include into the viral genome, and to optimize viral infection and/or replication selectively through targeted mutations.
1168:
834:"A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) - Full Text View - ClinicalTrials.gov"
1123:
992:
903:
1169:"SillaJen Announces Collaboration with the National Cancer Institute for Development of Combination Therapy with SillaJen's pexastimogene devacirepvec (Pexa-Vec) Oncolytic Immunotherapy"
717:
Zeh, Herbert J; Downs-Canner, Stephanie; McCart, J Andrea; Guo, Zong Sheng; Rao, Uma N M; Ramalingam, Lekshmi; Thorne, Stephen H; Jones, Heather L; Kalinski, Pawel (2015-01-01).
571:. In October 2015, SillaJen is selected as the major developer for the Government project of “Global State-of-the-art technology development for biomedical products."
1260:
626:
1124:"SillaJen and Lee's Pharmaceutical Announce Approval by the China CFDA to Commence Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer"
814:"A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) - Full Text View - ClinicalTrials.gov"
854:"Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. - Full Text View - ClinicalTrials.gov"
794:"Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone - Full Text View - ClinicalTrials.gov"
873:
993:"SillaJen Announces Agreement with the FDA for a Special Protocol Assessment for Upcoming Phase 3 Pexa-Vec Trial in Advanced Liver Cancer"
971:
1099:"Regeneron and SillaJen Announce Immuno-Oncology Clinical Study Agreement for Combination Treatment in Kidney Cancer (NASDAQ:REGN)"
719:"First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity"
793:
600:
140:
904:"Regeneron and SillaJen Announce Immuno-Oncology Clinical Study Agreement for Combination Treatment in Kidney Cancer"
853:
833:
615:
558:
278:
630:
596:
519:
515:
507:
578:
562:
489:
464:
399:
374:
352:
288:
189:
180:
813:
577:. In January 2016, SillaJen announces first patient randomized in its global Phase 3 trial for Pexa-Vec in
611:
538:
162:
947:
1098:
172:
1237:
881:
775:
692:
666:
72:
1186:
1141:
1010:
921:
756:
738:
1223:
746:
730:
1198:
1153:
1078:
1022:
933:
751:
718:
305:
50:
1254:
263:
247:
58:
642:
619:
459:
428:
437:
634:
586:
97:
1213:
638:
481:
420:
267:
216:
742:
1054:
503:
454:
344:
760:
548:
534:
391:
136:
39:
734:
255:
595:. In May 2017, SillaJen signs a clinical collaborative agreement with
582:
607:
424:
416:
259:
251:
91:
1036:
601:
immune checkpoint inhibitor cemiplimab for renal cell carcinoma
511:
153:
144:
633:
to conduct a clinical study in combination with Pexa-Vec and
599:
to conduct a combination study with Pexa-Vec and
Regeneron's
557:. In April 2015. SillaJen began a Phase 3 clinical trial of
1245:
230:
972:"SillaJen Announces Agreement to Acquire Jennerex, Inc"
1079:"Sillajen shares dip below IPO price on market debut"
225:
215:
205:
197:
124:
114:
104:
86:
78:
68:
56:
46:
35:
21:
776:"Development Pipeline > PIPELINE > Sillajen"
606:In July 2017, SillaJen received approval from the
627:cooperative research and development agreement
8:
27:
16:
693:"JX-900 Series > PIPELINE > Sillajen"
514:and clinical collaboration agreements with
1055:"215600:KOSDAQ Stock Quote - SillaJen Inc"
581:. In December 2016. SillaJen is listed on
368:Combined with metronomic cyclophosphamide
169:SillaJen, Biotherapeutics: Helena H. Chaye
15:
750:
310:
654:
1261:Biotechnology companies of South Korea
1194:
1184:
1149:
1139:
1018:
1008:
929:
919:
667:"SOLVE® > TECHNOLOGY > Sillajen"
660:
658:
7:
287:: VVDD Platform: Next-gen enhanced
14:
902:Inc., Regeneron Pharmaceuticals.
1230:
1216:
304:As of June 2018, these are the
948:"Jennerex Biotherapeutics Inc"
625:In Aug 2017, SillaJen signs a
1:
221:SillaJen Biotherapeutics Inc.
502:SillaJen has partnered with
1277:
631:National Cancer Institute
629:(CRADA or CRDA) with the
597:Regeneron Pharmaceuticals
520:National Cancer Institute
516:Regeneron Pharmaceuticals
334:Hepatocellular carcinoma
328:
322:
319:
316:
313:
250:company, with offices in
28:
541:, USA) was established.
406:Colorectal Cancer 2L/3L
381:Renal Cell Carcinoma 2L
308:investigating Pexa-Vec.
874:"Pexa-Vec Partnerships"
289:oncolytic immunotherapy
246:is a South Korea-based
1103:investor.regeneron.com
637:checkpoint inhibitors
163:Chief Strategy Officer
579:Advanced Liver Cancer
563:advanced liver cancer
512:Lee's Pharmaceuticals
547:. SillaJen acquires
110:4 (South Korea, USA)
735:10.1038/mt.2014.194
614:clinical trial for
262:, South Korea, and
207:Number of employees
106:Number of locations
18:
1238:South Korea portal
1197:has generic name (
1173:www.prnewswire.com
1152:has generic name (
1128:www.prnewswire.com
1021:has generic name (
997:www.prnewswire.com
932:has generic name (
908:www.prnewswire.com
774:INTERNET, CENTUM.
691:INTERNET, CENTUM.
665:INTERNET, CENTUM.
73:Biopharmaceuticals
952:BioCentury – BCIQ
723:Molecular Therapy
610:CFDA to commence
495:
494:
300:Pexa-Vec (JX-594)
241:
240:
201:Pexa-Vec (JX-594)
193:
184:
176:
166:
157:
148:
1268:
1240:
1235:
1234:
1233:
1226:
1224:Companies portal
1221:
1220:
1219:
1203:
1202:
1196:
1192:
1190:
1182:
1180:
1179:
1167:Inc., SillaJen.
1164:
1158:
1157:
1151:
1147:
1145:
1137:
1135:
1134:
1122:Inc., SillaJen.
1119:
1113:
1112:
1110:
1109:
1095:
1089:
1088:
1086:
1085:
1075:
1069:
1068:
1066:
1065:
1051:
1045:
1044:
1033:
1027:
1026:
1020:
1016:
1014:
1006:
1004:
1003:
991:Inc., SillaJen.
988:
982:
981:
979:
978:
968:
962:
961:
959:
958:
944:
938:
937:
931:
927:
925:
917:
915:
914:
899:
893:
892:
890:
889:
880:. Archived from
878:www.sillajen.com
870:
864:
863:
861:
860:
850:
844:
843:
841:
840:
830:
824:
823:
821:
820:
810:
804:
803:
801:
800:
790:
784:
783:
780:www.sillajen.com
771:
765:
764:
754:
714:
708:
707:
705:
704:
697:www.sillajen.com
688:
682:
681:
679:
678:
671:www.sillajen.com
662:
311:
237:
234:
232:
187:
178:
170:
160:
151:
134:
130:SillaJen, Inc:
31:
30:
19:
1276:
1275:
1271:
1270:
1269:
1267:
1266:
1265:
1251:
1250:
1236:
1231:
1229:
1222:
1217:
1215:
1212:
1207:
1206:
1193:
1183:
1177:
1175:
1166:
1165:
1161:
1148:
1138:
1132:
1130:
1121:
1120:
1116:
1107:
1105:
1097:
1096:
1092:
1083:
1081:
1077:
1076:
1072:
1063:
1061:
1053:
1052:
1048:
1035:
1034:
1030:
1017:
1007:
1001:
999:
990:
989:
985:
976:
974:
970:
969:
965:
956:
954:
946:
945:
941:
928:
918:
912:
910:
901:
900:
896:
887:
885:
872:
871:
867:
858:
856:
852:
851:
847:
838:
836:
832:
831:
827:
818:
816:
812:
811:
807:
798:
796:
792:
791:
787:
773:
772:
768:
716:
715:
711:
702:
700:
690:
689:
685:
676:
674:
664:
663:
656:
651:
528:
500:
306:clinical trials
302:
297:
295:Clinical trials
276:
229:
208:
159:
158:, Hyun-Pil Shin
150:
133:
127:
117:
107:
100:
94:
61:
24:
12:
11:
5:
1274:
1272:
1264:
1263:
1253:
1252:
1249:
1248:
1242:
1241:
1227:
1211:
1210:External links
1208:
1205:
1204:
1159:
1114:
1090:
1070:
1046:
1028:
983:
963:
939:
894:
865:
845:
825:
805:
785:
766:
729:(1): 202–214.
709:
683:
653:
652:
650:
647:
527:
524:
499:
496:
493:
492:
487:
484:
480:Combined with
478:
475:
472:
468:
467:
462:
457:
453:Combined with
451:
448:
445:
441:
440:
435:
432:
415:Combined with
413:
410:
407:
403:
402:
397:
394:
390:Combined with
388:
385:
382:
378:
377:
372:
369:
366:
363:
360:
356:
355:
350:
347:
343:Combined with
341:
338:
335:
331:
330:
327:
324:
321:
318:
315:
301:
298:
296:
293:
275:
272:
244:SillaJen, Inc.
239:
238:
227:
223:
222:
219:
213:
212:
209:
206:
203:
202:
199:
195:
194:
186:James M. Burke
149:Myung-Suk Song
128:
125:
122:
121:
118:
115:
112:
111:
108:
105:
102:
101:
96:
90:
88:
84:
83:
80:
76:
75:
70:
66:
65:
64:KOSDAQ: 215600
62:
57:
54:
53:
48:
44:
43:
37:
33:
32:
25:
22:
17:SillaJen, Inc.
13:
10:
9:
6:
4:
3:
2:
1273:
1262:
1259:
1258:
1256:
1247:
1244:
1243:
1239:
1228:
1225:
1214:
1209:
1200:
1188:
1174:
1170:
1163:
1160:
1155:
1143:
1129:
1125:
1118:
1115:
1104:
1100:
1094:
1091:
1080:
1074:
1071:
1060:
1059:Bloomberg.com
1056:
1050:
1047:
1042:
1038:
1037:"글로벌첨단바이오의약품"
1032:
1029:
1024:
1012:
998:
994:
987:
984:
973:
967:
964:
953:
949:
943:
940:
935:
923:
909:
905:
898:
895:
884:on 2017-11-04
883:
879:
875:
869:
866:
855:
849:
846:
835:
829:
826:
815:
809:
806:
795:
789:
786:
781:
777:
770:
767:
762:
758:
753:
748:
744:
740:
736:
732:
728:
724:
720:
713:
710:
698:
694:
687:
684:
672:
668:
661:
659:
655:
648:
646:
644:
640:
636:
635:AstraZeneca's
632:
628:
623:
621:
617:
613:
609:
604:
602:
598:
594:
590:
588:
584:
580:
576:
572:
570:
566:
564:
560:
556:
552:
550:
546:
542:
540:
539:San Francisco
536:
532:
525:
523:
521:
517:
513:
509:
505:
497:
491:
488:
486:Investigator
485:
483:
479:
476:
473:
471:Solid Tumors
470:
469:
466:
463:
461:
458:
456:
452:
449:
446:
444:Liver Cancer
443:
442:
439:
436:
434:Investigator
433:
430:
426:
422:
418:
414:
411:
408:
405:
404:
401:
398:
395:
393:
389:
386:
383:
380:
379:
376:
373:
371:Investigator
370:
367:
364:
361:
359:Solid Tumors
358:
357:
354:
351:
348:
346:
342:
339:
336:
333:
332:
325:
312:
309:
307:
299:
294:
292:
290:
286:
285:JX-900 (VVDD)
282:
280:
273:
271:
269:
265:
264:San Francisco
261:
257:
253:
249:
248:biotechnology
245:
236:
228:
224:
220:
218:
214:
210:
204:
200:
196:
191:
185:
182:
174:
167:
164:
155:
146:
142:
138:
132:Eun-Sang Moon
129:
123:
119:
113:
109:
103:
99:
93:
89:
85:
81:
77:
74:
71:
67:
63:
60:
55:
52:
49:
45:
41:
38:
34:
26:
20:
1176:. Retrieved
1172:
1162:
1131:. Retrieved
1127:
1117:
1106:. Retrieved
1102:
1093:
1082:. Retrieved
1073:
1062:. Retrieved
1058:
1049:
1040:
1031:
1000:. Retrieved
996:
986:
975:. Retrieved
966:
955:. Retrieved
951:
942:
911:. Retrieved
907:
897:
886:. Retrieved
882:the original
877:
868:
857:. Retrieved
848:
837:. Retrieved
828:
817:. Retrieved
808:
797:. Retrieved
788:
779:
769:
726:
722:
712:
701:. Retrieved
696:
686:
675:. Retrieved
670:
643:tremelimumab
624:
605:
592:
591:
574:
573:
568:
567:
554:
553:
544:
543:
530:
529:
522:for JX-594.
501:
498:Partnerships
460:Transgene SA
429:tremelimumab
303:
284:
283:
277:
243:
242:
217:Subsidiaries
168:
131:
87:Headquarters
47:Company type
1195:|last=
1150:|last=
1041:글로벌첨단바이오의약품
1019:|last=
930:|last=
699:(in Korean)
673:(in Korean)
587:South Korea
518:and the US
508:Green Cross
490:NCT02977156
477:Recruiting
465:NCT03071094
450:Recruiting
438:NCT03206073
412:Recruiting
400:NCT03294083
387:Recruiting
375:NCT02630368
365:Recruiting
353:NCT02562755
340:Recruiting
314:Indication
177:Georg Roth
116:Area served
98:South Korea
23:Native name
1178:2018-06-17
1133:2018-06-17
1108:2018-06-17
1084:2018-06-17
1064:2018-06-17
1002:2018-06-17
977:2018-06-17
957:2018-06-17
913:2018-06-16
888:2018-06-16
859:2018-06-16
839:2018-06-16
819:2018-06-16
799:2018-06-16
703:2018-06-17
677:2018-06-17
649:References
639:durvalumab
585:market in
482:Ipilimumab
421:durvalumab
274:Technology
268:California
126:Key people
743:1525-0016
618:in liver
504:Transgene
455:Nivolumab
396:SillaJen
349:SillaJen
345:sorafenib
233:.sillajen
141:President
120:Worldwide
59:Traded as
1255:Category
1246:Homepage
1187:cite web
1142:cite web
1011:cite web
922:cite web
761:25292189
616:Pexa-Vec
559:Pexa-Vec
549:Jennerex
537:, Inc. (
535:Jennerex
392:REGN2810
326:Sponsor
279:Pexa-Vec
198:Products
137:Chairman
69:Industry
40:Jennerex
36:Formerly
752:4426804
612:phase 3
551:, Inc.
526:History
320:Status
256:Yangsan
226:Website
79:Founded
759:
749:
741:
620:cancer
583:KOSDAQ
510:, and
423:) and
323:Notes
317:Phase
143:, and
51:Public
608:China
425:CTLA4
417:PD-L1
260:Seoul
252:Busan
92:Busan
42:, Inc
1199:help
1154:help
1023:help
934:help
757:PMID
739:ISSN
641:and
593:2017
575:2016
569:2015
555:2015
545:2014
531:2003
337:III
329:Ref
258:and
235:.com
211:~100
82:2003
747:PMC
731:doi
561:in
362:II
231:www
190:CMO
183:),
181:COO
175:),
173:CBO
154:CFO
145:CEO
29:신라젠
1257::
1191::
1189:}}
1185:{{
1171:.
1146::
1144:}}
1140:{{
1126:.
1101:.
1057:.
1039:.
1015::
1013:}}
1009:{{
995:.
950:.
926::
924:}}
920:{{
906:.
876:.
778:.
755:.
745:.
737:.
727:23
725:.
721:.
695:.
669:.
657:^
645:.
622:.
603:.
589:.
565:.
533:.
506:,
474:I
447:I
431:)
409:I
384:I
291:.
270:.
266:,
254:,
139:,
95:,
1201:)
1181:.
1156:)
1136:.
1111:.
1087:.
1067:.
1043:.
1025:)
1005:.
980:.
960:.
936:)
916:.
891:.
862:.
842:.
822:.
802:.
782:.
763:.
733::
706:.
680:.
427:(
419:(
192:)
188:(
179:(
171:(
165:)
161:(
156:)
152:(
147:)
135:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.